In a prior study of selumetinib, roughly half of the cell lines exposed to selumetinib had IC50 values > 1μM, whereas in the current study, 42 of 54 CRC cell lines exhibited robust sensitivity to TAK-733, as defined by an IC50 ≤ 0.02 μM, with the majority being KRAS or BRAF mutant. Here, BRAF is linked to colorectal carcinoma.